Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12372621
Morisaki T, et al. (2002) WARTS tumor suppressor is phosphorylated by Cdc2/cyclin B at spindle poles during mitosis. FEBS Lett 529, 319-24 12372621
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T490-p - LATS1 (human)
Modsite: ATTVTAItPAPIQQP SwissProt Entrez-Gene
Orthologous residues
LATS1 (human): T490‑p, LATS1 (mouse): T489‑p, LATS1 (rat): T490‑p

S613-p - LATS1 (human)
Modsite: EKKQITtsPItVRKN SwissProt Entrez-Gene
Orthologous residues
LATS1 (human): S613‑p, LATS1 (mouse): S612‑p, LATS1 (rat): S613‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) activation of upstream enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase